Dr Pang joined the School of Public Health in 2013 after working as an assistant professor for over five years in the Department of Biostatistics and Bioinformatics at Duke University. He obtained his PhD in Biostatistics from Yale University in 2008 and BA in Mathematics and Computer Science from the University of Oxford in 2002.
His primary research interests include big data, biomarker discovery in clinical studies, cancer genomics, classification, data science, design and analysis of clinical trials, machine learning, meta-analysis, metagenomics, multi-omics data integration, predictive models, and translational medicine. He was a principal investigator on an NIH R21 grant entitled ‘Translational Meta-analysis for Elderly Lung Cancer Patients’ from the National Institute on Aging. He is currently a principal investigator on an RGC grant entitled 'A Familial Meta -Omics Study of the Cutaneous Microbiome in Psoriasis' and an HMRF grant entitled ‘Modelling chemotherapy-induced neutropenia and other hematologic toxicities in elderly patients’.
Dr Pang has published over 80 methodological and translational peer-reviewed research articles on statistics, genetics, genomics, bioinformatics, and clinical trials. From January 2012 to December 2014, he served on the editorial board of the Journal of Clinical Oncology. He has also contributed as a reviewer for over 40 leading journals, such as Annals of Applied Statistics, Bioinformatics, Biostatistics, Genome Biology, JAMA Oncology, Nucleic Acids Research, Science Translational Medicine, Statistics in Medicine, and Trends in Genetics. He holds an adjunct faculty position in the Department of Biostatistics and Bioinformatics at Duke University School of Medicine. He is a member of the American Statistical Association and a fellow of the Royal Statistical Society.
Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, Berry MF, Schrag D, Pang H. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst. 2017 Aug 1;109(8). [2018 IF=11.2] (Rank 10 out of 222 under the category of “Oncology”)
Pang H, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, Adjei AA, Gandara D, Ramalingam SS, Vokes EE. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 Nov 20;34(33):3992-3999. [2018 IF=26.4] (Rank 4 out of 222 under the category of “Oncology”)
Ready NE, Pang H, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. [2018 IF=26.4] (Rank 4 out of 222 under the category of “Oncology”)
Ni MY, Chan BH, Leung GM, Lau EH, Pang H. Transmissibility of the Ice Bucket Challenge among globally influential celebrities: retrospective cohort study. BMJ. 2014 Dec 16;349:g7185. [2018 IF=23.6] (Rank 4 out of 155 under the category of “Medicine, General & Internal”)
Murphy SK, Yang H, Moylan CA, Pang H, Dellinger A, Abdelmalek MF, Garrett ME, Ashley-Koch A, Suzuki A, Tillmann HL, Hauser MA, Diehl AM. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology. 2013 Nov;145(5):1076-87. [2018 IF=20.8] (Rank 1 out of 80 under the category of “Gastroenterology & Hepatology”)
Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S; Surrogate Lung Project Collaborative Group. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol. 2013 Jun;14(7):619-26. [2018 IF=36.4] (Rank 3 out of 222 under the category of “Oncology”)
Pang H, Jung SH. Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes. Genet Epidemiol. 2013 Apr;37(3):276-82. [2018 IF=2.5] (Rank 9 out of 161 under the category of “Mathematical & Computational Biology”)
Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013 Apr 3;309(13):1359-67. [2018 IF=47.7] (Rank 3 out of 155 under the category of “Medicine, General & Internal”)
Pang H, George SL, Hui K, Tong T. Gene selection using iterative feature elimination random forests for survival outcomes. IEEE/ACM Trans Comput Biol Bioinform. 2012 Sep-Oct;9(5):1422-31. [2018 IF=2.4] (Rank 12 out of 123 under the category of “Statistics & Probability”)
Pang H, Lin A, Holford M, Enerson BE, Lu B, Lawton MP, Floyd E, Zhao H. Pathway analysis using random forests classification and regression. Bioinformatics. 2006 Aug 15;22(16):2028-36. [2018 IF=5.5] (Rank 3 out of 59 under the category of “Mathematical & Computational Biology”)